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A kinetic analysis of the inhibition of FOX-4 b-lactamase,
a plasmid-mediated AmpC cephalosporinase, by monocyclic
b-lactams and carbapenems
Krisztina M. Papp-Wallace , Susana Mallo , Christopher R. Bethe , Magdalena A. Taracila , Andrea M. Hujer ,
Ana Ferna´ndez , Julian A. Gatta , Kerri M. Smith , Yan Xu , Malcolm G. P. Page , Eric Desarbre ,
Germa´n Bou and Robert A. Bonomo
Objectives:Class Cb lactamases are prevalent among Enterobacteriaceae; however, these enzymes are resistant
to inactivation by commercially available b lactamase inhibitors. In order to find novel scaffolds to inhibit class C
b lactamases, the comparative efficacy of monocyclic b lactam antibiotics (aztreonam and the siderophore
monosulfactam BAL30072), the bridged monobactam b lactamase inhibitor BAL29880, and carbapenems (imi
penem, meropenem, doripenem and ertapenem) were tested in kinetic assays against FOX 4, a plasmid mediated
class C b lactamase (pmAmpC).
Methods: The FOX 4 b lactamase was purified. Steady state kinetics, electrospray ionization mass spectrometry
(ESI MS) and ultraviolet difference (UVD) spectroscopy were conducted using the b lactam scaffolds described.
Results: The Ki values for the monocyclicb lactams against FOX 4b lactamase were 0.04+0.01 mM (aztreonam)
and 0.66+0.03 mM (BAL30072), and the Ki value for the bridged monobactam BAL29880 was 8.9+0.5 mM.
For carbapenems, the Ki values ranged from 0.27+0.05 mM (ertapenem) to 2.3+0.3 mM (imipenem). ESI MS
demonstrated the formation of stable covalent adducts when the monocyclic b lactams and carbapenems
were reacted with FOX 4 b lactamase. UVD spectroscopy suggested the appearance of different chromophoric
intermediates.
Conclusions: Monocyclic b lactam and carbapenem antibiotics are effective mechanism based inhibitors of
FOX 4 b lactamase, a clinically important pmAmpC, and provide stimulus for the development of new inhibitors
to inactivate plasmidic and chromosomal class C b lactamases.
Keywords: bridged monobactams, monosulfactam, b lactamase inhibitors, carbapenems
Introduction
The prevalence and dissemination of plasmid mediated class C
b lactamases (pmAmpCs) is a critical challenge in the treatment
of infections caused by Gram negative bacteria.1,2 Clinically
important pmAmpCs include the CMY, MIR, MOX, LAT, FOX, DHA,
ACT, ACC and CFE b lactamase families.2 The FOX family of
class C cephalosporinases is distinctly different in amino acid
sequence when compared with other class C b lactamases.3 All
eight variants of the FOX family of b lactamases that have been
described thus far show substrate specificity for cephalosporins,
including cephamycins.2,4 9 Studies have indicated that blaFOX
is widely disseminated in the USA, is present on IncA/C and
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pMG252 plasmids, and is often associated with the presence of
plasmid mediated quinolone resistance determinants, qnr.8,10 19
FOX b lactamases have also been found outside the USA – in
Europe, Central and South America, and India.4 7,20,21 Significantly,
the presence of FOX b lactamases can complicate the laboratory
detection of extended spectrum b lactamases by yielding false
positive or false negative results.19
In this study, FOX 4 was selected from the FOX familyas a model
b lactamase because the clinical impact of this class of pmAmpC
is notable. blaFOX 4 was identified in an Escherichia coli clinical
strain isolated from a patient with a urinary tract infection in
Spain.7 FOX 4 possesses broad substrate specificity for b lactam
hydrolysis, especially cephamycins, the biochemical basis of
which remains to be explored. The kinetic inhibitory profiles of
monocyclicb lactams and carbapenems against FOX 4 were investi
gated in this analysis to determine whether these compounds have
broad inhibitory profiles against plasmid encoded cephamycinases.
To date, studies of the inhibition of class C enzymes by
b lactamase inhibitors have focused on a select or restricted
number of enzymes (e.g. AmpC of E. coli, and ADC 7, CMY 2 and
AmpC of Pseudomonas aeruginosa).22 28 These studies do not
fully define the mechanistic basis of AmpC inhibition. To illustrate,
Bauvois et al.29 showed that the affinity constants of pmAmpCs
were significantly different compared with chromosomal AmpCs
and that enzyme production in the periplasmic space is variable.
These uncertainties merit more careful study.
Class C cephalosporinases are usually resistant to the action of
commercially availableb lactamase inhibitors (i.e. clavulanic acid,
sulbactam and tazobactam). The search for new compounds,
including b lactamase stable antibiotics and inhibitors of these
enzymes, therefore assumes paramount importance.30 Many ex
perimental b lactamase inactivators have been described and at
least three are in clinical development (i.e. avibactam, MK 7655
and RPX7009).31,32 However, some years will pass before any
reach clinical use.
As an antimicrobial agent, aztreonam effectively inhibits class C
b lactamases by acting as a poor substrate because its C4 methyl
substituent prevents rotation that would otherwise expose the
ester bond of the acyl adduct to hydrolytic attack.29,33 The
bridged monobactams were designed to exploit this principle,34
and BAL29880, which does not have intrinsic antimicrobial proper
ties, has been shown to be an effective class C b lactamase inhibi
tor.24,35The siderophore monosulfactam BAL30072 (bearing a side
chain that can enhance its entry to cells through bacterial iron
uptake systems) is effective against many cephalosporin and
carbapenem resistant strains.24,36,37 The potential of BAL30072 as
a broad based inhibitor of class C b lactamases has not been fully
evaluated.
Carbapenems such as imipenem were shown to act as class C
b lactamase inhibitors,2,24,38,39 and were studied as inhibitors
of the P. aeruginosa and E. coli class C b lactamases as well as
of CMY 2 and ADC 7.22 24,40 These molecules form stable acyl–
enzyme adducts in which the 6a hydroxyethyl side chain is
believed to force the electrophilic acyl centre to rotate away from
the point of hydrolytic attack.39 The high apparent affinity of
carbapenems for class C b lactamases makes them attractive
candidates for further development as drugs with dual properties
(i.e. as antibiotics and b lactamase inhibitors).38,39
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Materials and methods
Antibiotics
Ampicillin was obtained from Sigma (St Louis, MO, USA). Aztreonam was
purchased from Elan (Dublin, Ireland). Nitrocefin (NCF) was supplied by
BD Biosciences (San Jose, CA, USA). Doripenem was obtained from Janssen-
Cilag (Neuss, Germany), ertapenem and imipenem were purchased from
Merck (Whitehouse Station, NJ, USA) and meropenem was procured from
AstraZeneca Pharmaceuticals (Wilmington, DE, USA). BAL29880 and
BAL30072 were prepared in the laboratories of Basilea Pharmaceutica
International Ltd (Basel, Switzerland). The chemical structures of the
monobactams and carbapenems tested are shown in Figure 1.
Plasmids and strains
The cloning of the blaFOX-4 gene into pGEX-6p-1 and pBGS18 was previously
reported.3 The pGEX-6p-1 clone in E. coli BL21 (DE3) was used for protein
expression. The pBGS18 clone expressed in E. coli TG1 was used for anti-
microbial susceptibility testing.
Protein expression and purification
The expression and purification of the FOX-4 b-lactamase was previously
described.3
Kinetic parameters
The purified enzyme was used in all the studies reported here. Kinetic
experiments were carried out with an Agilent 8453 diode array spectro-
photometer at room temperature in 10 mM PBS buffer at pH 7.4. Vmax
and Km were determined from initial steady-state velocities for NCF,
D1482¼17400 M 1 cm 1. These parameters were calculated using
iterative non-linear least-squares fit of the data to the Henri Michaelis
Menten equation using EnzfitterTM (Biosoft Corporation) according to
Equation 1:
v Vmax
[S]
(Km + [S]) (1)
Here, v is observed velocity, Vmax is maximum velocity, [S] is substrate con-
centration and Km is the Michaelis constant.
The simplified scheme in Figure 2 depicts the interactions of FOX-4 with
inhibitors chosen for this study. Ki values correspond to a relative affinity or
k 1/k1 of the inhibitor for the enzyme (for inhibitors that acylate slowly) or
to the Michaelis constant or (k 1+k2)/k1 of the inhibitor for the enzyme
(for inhibitors that acylate more rapidly). Ki was determined by direct
competition assays using 200 mM NCF. Inverse initial steady-state velocities
(1/v0)wereplottedagainst the inhibitorconcentration ([I]) toobtaina straight
line. The v0 measured after mixing is represented by Equation 2:
v0
(Vmax × [S])
(Km(NCF) × (1 + [I]/Km) + [S]) (2)
The plots were linear and provided y-intercept and slope values used for
Ki determination. Ki was determined bydividing the value for they-intercept
by the slope of the line and then corrected by taking into account the NCF
affinity (Equation 3):
Ki(corrected)
Ki(observed)
(1 + [S]/Km) (3)
Here, [S] is the concentration of NCF (200 mM) used in the assayand Km isthe
Michaelis constant determined for NCF (74 mM).
Progress curves with a fixed concentration of enzyme and NCF, and
increasing inhibitor concentration, were used to determine the kinact and
KI values, as previously described.
41 kinact values indicate the number of
molecules of enzyme that are inactivated per second; a higher value
equates to a more rapid inactivation of the enzyme by the inhibitor. The
KI value corresponds to the concentration of inhibitor required to reach 12
kinact. Progress curves were fit to Equation 4 to obtain kobs values using itera-
tive non-linear least-squares fit of the data employing Origin 7.5 software.
A A0 + vf × t + (v0 vf ) ×
[1 e(−kobs×t)]
kobs
(4)
Here, A is absorbance, v0 (expressed in variation of absorbance per unit
time) is initial velocity, vf is final velocity and t is time. kobs was plotted
E + I E:I E-I E-I* E + P
k1 k2 k3 k4
k–1
Figure 2. Interactions of FOX-4 (E) with inhibitors (I) are depicted by this reaction scheme. The formation of the Michaelis complex E:I is represented by the
dissociation constant K¼k 1/k1. k2 is the first-order rateconstant foracylation or formation of E-I. The appearance of chromophores (E-I*), as suggested by
UVD spectroscopy, is represented by the rate constant k3. Finally, product formation (E+P) as revealed by tn.1 for the majority of the compounds tested is
denoted by the rate constant k4.
Table 1. Steady-state kinetic inhibition parameters for FOX-4 with monocyclic b-lactams and carbapenems
Inhibitor Ki (mM) KI (mM) kinact (s
1) kinact/KI (mM
1 s 1) tn (15 min) tn (24 h)
Aztreonam 0.04+0.01 0.010+0.001 0.05+0.01 5+1 1 1
BAL29880 9+1 41+4 0.34+0.03 0.010+0.001 20 1
BAL30072 0.7+0.1 0.35+0.01 0.10+0.01 0.29+0.03 70 80
Doripenem 1.1+0.1 1.4+0.2 0.19+0.02 0.14+0.02 50 80
Ertapenem 0.27+0.05 0.09+0.02 0.10+0.01 1.1+0.2 3 60
Imipenem 2.3+0.3 10+1 0.37+0.04 0.04+0.01 80 100
Meropenem 0.28+0.04 0.13+0.01 0.08+0.01 0.62+0.08 15 40
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versus the inhibitor concentrations of the experiment and fit to determine
kinact according to Equation 5. The KI value obtained was corrected using
Equation 3.
kobs
kinact[I]
(KI + [I]) (5)
Turnover numbers (tn) or partition ratios (kcat/kinact) are defined herein as
the ratio of inhibitor concentration to enzyme concentration necessary to
decrease the enzyme activity by 95%. tn corresponds to the number of
inhibitor molecules an enzyme turns over before the enzyme is inhibited;
thus, the lower the number the more effective the inhibitor for the time
period measured. The tn values were determined after 15 min and 24 h of
incubation with increasing concentrations of the inhibitor. Incubations
were done in a final volume of 300 mL, and 25 mL of this reaction mixture
was added to a 1 mL final volume to determine the residual enzyme
activity using 200 mM NCF.
Ultraviolet difference (UVD) spectroscopy and formation
of spectroscopic intermediates
To monitor the appearance of chromophore intermediates, UVD spectros-
copy was conducted using a molar ratio of 1000:1 (inhibitor/enzyme)
from l¼200 350 nm as previously described.42 Measurements were
made every 12 s for 60 min.
Electrospray ionization mass spectrometry (ESI-MS)
b-Lactamase analysis was carried out on an Applied Biosystems (Foster
City, CA, USA) QSTARw-Elite quadrupole time-of-flight (Q-TOF) mass spec-
trometer equipped with a TurboIon sprayTM source and an integrated
syringe pump. Mass calibration was performed in the positive mode with
renin solution, using the validated instrument protocol. Enzyme-to-
inhibitor ratios were based on the amount of inhibitor required to inactivate
.95% of the enzyme after 15 min or the tn at 15 min. The reaction mixtures
of protein and inhibitor were desalted using C18 ZipTips (Millipore, Bedford,
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Figure 3. UVD spectroscopy of FOX-4 reacted with (a) BAL29880, (b) aztreonam and (c) BAL30072. Absorbance (Abs) values in arbitrary units (a.u.) were
measured from wavelengths of 200 350 nm at 12 s (solid line), 15 min (dotted line), 30 min (dashed line), 45 min (smaller dashed line) and 60 min
(dashed-dotted line) timepoints.
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MA, USA) according to the protocol recommended by the manufacturer. The
protein was eluted from the ZipTips in 50 mL of acetonitrile/H2O/formic acid
(50:49:1) before analysis. The protein eluate was then infused into the
mass spectrometer at a flow rate of 5 mL/min. Mass spectra were acquired
using Analyst QS v2.0 software with 80 MCA cycles and an accumulation
time of 1.5 s. The mass spectra were deconvoluted by BioAnalystTM 2.0 soft-
ware using the Bayesian protein reconstruction algorithm.
Antimicrobial susceptibility testing
Agar dilution was used to determine the MICs of ampicillin, aztreonam,
BAL29880, BAL30072, doripenem, ertapenem, imipenem and meropenem
alone and ampicillin in combination with aztreonam, BAL29880 and
BAL30072. For combination experiments, the concentrations of BAL29880,
BAL30072 and aztreonam were fixed at 4 mg/L.
Results
Inhibition kinetics
Kinetic parameters of inhibition for the monocyclicb lactams and car
bapenems are summarized in Table 1. Aztreonam possessed the
lowest Ki and KI values, at 0.04+0.01 mM and 0.010+0.001 mM, re
spectively, while BAL29880 demonstrated the highest Ki and KI
values, at 9+1 mM and 41+4 mM, respectively. The inactivation effi
ciencies (i.e. kinact/KI) were the lowest for BAL29880 and imipenem
at 0.010+0.001 mM 1 s 1 and 0.04+0.01 mM 1 s 1, respectively,
and highest for ertapenem and aztreonam at 1.1+0.2 mM 1 s 1
and 5+1 mM 1 s 1, respectively. BAL30072 displayed an inactivation
efficiencysimilar to those of meropenem and doripenem (0.29+0.03,
0.62+0.08 and 0.14+0.02 mM 1 s 1, respectively). The partition
ratio (kcat/kinact) for aztreonam and BAL29880 was 1 at 24 h. For the
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Figure 4. Deconvoluted mass spectra of FOX-4 b-lactamase alone and with inhibitors in variable ratios (in parentheses). Mass increases (products of
inactivation) are shown for (a) FOX-4 b-lactamase alone, (b) FOX-4 with aztreonam, (c) FOX-4 with BAL29880 and (d) FOX-4 with BAL30072. All
measurements have an error of+5 amu.
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other compounds tested,≥40 molecules of inhibitor were required to
decrease FOX 4 activity by 95% after 24 h; thus, these compounds
appear to be slowly hydrolysed by FOX 4. Fewer molecules were
required to inhibit FOX 4 activity after 15 min for most inhibitors,
except for BAL29880, which may be due to its large Ki and KI values
for FOX 4.
UVD spectroscopy
UVD spectroscopy was used to detect the presence of intermedi
ates (chromophores) formed during the inactivation process.
A clear peak in the difference spectrum of the reaction mixture of
FOX 4 and BAL29880 occurred at l¼255 nm (Figure 3a). A0
at l¼255 nm increased rapidly to a stable level (representing for
mation of the acyl–enzyme adduct). Surprisingly, the formation
of chromophores was distinctly different when aztreonam and
BAL30072 were reacted with FOX 4. The difference spectrum of
these reaction mixtures showed the formation of chromophores
at l¼215 nm and l¼290 nm with aztreonam, and at
l¼235 nm and l¼290 nm with BAL30072 (Figure 3b and c).
The UVD spectra revealed that the chemistry of BAL29880 upon
interaction with FOX 4 is different from that of aztreonam and
BAL30072, as different chromophores are formed.
ESI-MS
ESI MS was employed to gain insight into the nature of the stable
covalent intermediates formed in the inactivation of the FOX 4
b lactamase. The expected mass of FOX 4 was 39230+5 amu,
as the recombinant enzyme consists of FOX 4 residues 24 to 382
plus eight extra residues (GPLGSPEF) at the amino terminus follow
ing cleavage of the fused N terminal GST tag expressed from the
pGEX 6p 1 vector (Figure 4a and Table 2).
FOX 4 inactivated by aztreonam produced the full adduct of az
treonam equivalent toD+437+5 amu, as well as another smaller
adduct of D+356+5 amu (Figure 4b and Table 2). The smaller
adduct is hypothesized to represent the complexed b lactamase
with elimination of the SO3
2 of aztreonam.24 Complete adducts
were found for FOX 4 in combination with BAL29880 and
BAL30072 (D +412+5 amu and D +519+5 amu, respectively)
(Figure 4c and d, and Table 2).
Each combination of FOX 4 with a carbapenem demonstrated
the full carbapenem complexed b lactamase, as well as an add
itional peak representing the acyl–enzyme complex with elimin
ation of the C6 hydroxyethyl side chain of the carbapenem
(Figure 5a–d and Table 2).23,24,43,44 For all tested combinations,
FOX 4 enzyme alone (39230 amu) was not identified, indicating
complete inactivation of FOX 4. An unexpected mass of
39560+5 amu was seen in most cases; the nature of this
species remains under investigation.
Antimicrobial susceptibility assays
To determine the antibacterial properties of the compounds
studied and relate these to the biochemical analyses, agar dilution
MICs were determined for the monocyclicb lactams and carbape
nems, and the data are presented in Table 3. For E. coli TG1 with
pBGS18 blaFOX 4, MICs were the lowest for BAL30072, doripenem,
ertapenem, meropenem and ampicillin/aztreonam, at 0.06 mg/
L, and highest for BAL29880, at.256 mg/L.
Discussion
The clinically used b lactamase inhibitors (clavulanic acid, sulbac
tam and tazobactam) have limited activity against class C
b lactamases; ampicillin and ceftazidime MICs for E. coli TG1
carrying blaFOX 4 are completely unaffected when combined
with these inhibitors.3,30There is therefore a growingneed to identify
novel compounds that are active against these enzymes. In
this context, the aim of this study was to test different monocyclic
b lactams (aztreonam and a siderophore monosulfactam,
BAL30072), a bridged monobactam (BAL29880) and carbapenems
for their ability to inhibit the class C b lactamase FOX 4.
Among the monocyclic b lactams, aztreonam showed the
highest inactivation efficiency (kinact/KI¼5+1 mM 1 s 1), owing
to a very low KI (0.01+0.001 mM), followed by BAL30072 and
then BAL29880. BAL29880 inactivates FOX 4 rapidly, with a high
Table 2. Mass spectrometry of FOX-4 alone and in combination with monocyclic b-lactams and carbapenems
Theoretical mass amu (+5) Experimental mass amu (+5) Experimental mass D amu (+5)
FOX-4 39230 39230
FOX-4+aztreonam (435 Da) 39665 39667 437
39586 356
FOX-4+BAL29880 (412 Da) 39642 39642 412
FOX-4+BAL30072 (518 Da) 39748 39749 519
FOX-4+doripenem (420 Da) 39650 39653 423
39609 379
FOX-4+ertapenem (475 Da) 39705 39707 477
39663 433
FOX-4+meropenem (383 Da) 39613 39614 384
39565 335
FOX-4+ imipenem (299 Da) 39529 39533 303
39489 259
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kinact value of 0.34+0.03 s
1; however, BAL29880 is slow to bind
and/or acylate the enzyme, as evidenced by high Ki, KI and tn
values at 15 min. The tn at 24 h for aztreonam and BAL29880
were both 1, which shows that recovery was not detected after
24 h of incubation and that these inhibitors are not hydrolysed by
FOX 4. These data are in accordance with previous results obtained
with BAL29880 as an inhibitor of CMY 2.24 The kinact/KI values are
identical for CMY 2 and FOX 4 at 0.01 mM 1 s 1. In bacteria,
BAL30072 was the most effective monocyclic b lactam, with an
MIC of 0.06 mg/L; this may be owing to the enhanced ability
BAL30072 to enter cells as a result of its siderophore side chain.
These observations were anticipated, as the suspected mech
anism of inactivation by aztreonam and BAL29880 depends
upon restricted rotation in the acyl adduct and blockade of the tra
jectoryof the hydrolytic water molecule.33,34It has been noted that
the monosulfactams form less stable adducts with class C
b lactamases, probably because of the greater flexibility of the
N O SO3 group compared with N SO3 .
45
Ertapenem was the best carbapenem inhibitor of FOX 4, with a
kinact/KI value of 1.1+0.2 mM
1 s 1, followed closely by merope
nem (0.62+0.08 mM 1 s 1); as with aztreonam, this is mostly
due to low KI values (0.09+0.02 mM and 0.13+0.01 mM, respect
ively). Imipenem and doripenem demonstrated higher KI values
and thus were less effective inhibitors by comparison. The kinact
values were similar for all the carbapenems, indicating that they
inactivate FOX 4 at similar rates. In bacteria, all the carbapenems
were similarly effective against E. coli TG1 pBGS18 blaFOX 4, as
evidenced by their MIC values of 0.06–0.25 mg/L. In clinical
practice, the use of ertapenem is more limited than the other
carbapenems because of its lack of activity against P. aeruginosa
and Acinetobacter baumannii,46,47 but its in vivo t1/2 is greater
than those of the other carbapenems.48
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Figure5. Deconvoluted mass spectra of FOX-4b-lactamase with inhibitors in variable ratios (in parentheses). Mass increases (products of inactivation) are
shown for (a) FOX-4b-lactamase with ertapenem, (b) FOX-4 with meropenem, (c) FOX-4 with doripenem and (d) FOX-4 with imipenem. All measurements
have an error of+5 amu.
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Conclusions
In summary, our testing of aztreonam, new monocyclicb lactams
and carbapenems against a pmAmpC, FOX 4, offers a better
understanding of their inhibitory behaviour against enzymes with
a substrate preference for cephamycins. The data we report here
propose a rationale to use both these classes of compounds with
dual properties for the treatment of infections caused by microor
ganisms possessing the blaFOX 4 gene; one exception is BAL29880,
which must be partnered with a b lactam for activity.38,39 Further
spectroscopic and structural studies are warranted to decipher
the nature of the intermediates suggested by the UVD studies.
The novel chromophores are suspected to occur due to differences
in the chemistry of the R1 side chains, which may be important for
FOX 4 inactivation by these compounds.
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